pharmaceutical lobbying Archives

The False Promise of U.S. Healthcare Reform: Why Costs Keep Rising

Brian RogersJune 5, 20240138 views

Despite government-led initiatives aimed at reducing healthcare costs, such as the Affordable Care Act enhancements and drug price negotiations, these measures have largely failed to provide significant savings for the average American. This article explores the reasons behind the ineffectiveness of these programs, comparing them to the systems in other countries, and examines whether they serve more to maintain the status quo than to deliver meaningful reform.

Commercial Protectionism vs. Affordable Pharmaceuticals: Navigating the Complex Landscape of U.S. Healthcare Policy

Brian RogersJune 5, 20240153 views

In the ongoing debate between commercial protectionism and the accessibility of affordable pharmaceuticals, the United States finds itself at a critical juncture. While the FDA’s stringent regulations on imported generics from countries like India are justified by health concerns, there is a growing perception that these measures increasingly serve commercial interests. Critics argue that the influence of Big Pharma has led to policies that prioritize corporate profits over consumer welfare, resulting in higher healthcare costs for Americans. This article explores the origins of these regulatory measures, the role of pharmaceutical lobbying, and the economic impacts of protectionism, calling for reforms to balance safety with affordability and accessibility.

Big Pharma’s Best Friend: The FDA Exposed

Brian RogersJune 2, 20240132 views

The Food and Drug Administration (FDA), once a trusted guardian of public health, now faces criticism for its close ties with Big Pharma, earning nicknames like “Federal Deceit Advocates” and “Federal Drug Atrocities.” This article examines the FDA’s failures, its revolving door with the pharmaceutical industry, and how corporate protectionism has overshadowed public health. With high-profile drug approval failures like the opioid crisis and Vioxx scandal, and financial dependency on pharmaceutical user fees, the FDA’s actions often prioritize corporate profits over public welfare. To restore trust and integrity, significant reforms are necessary, focusing on reducing conflicts of interest and increasing transparency.

How Big Pharma, the FDA, Congress, and Shadow Organizations Violate Our Constitutional Rights to Healthcare

Brian RogersMay 31, 20240137 views

The American healthcare system is often lauded as one of the most advanced in the world, but beneath the surface lies a troubling reality of collusion involving Big Pharma, the FDA, Congress, and shadow organizations like LegitScript. These entities, created to protect public health, prioritize corporate profits over individual rights and access to affordable healthcare. This article exposes how these powerful groups manipulate regulations, lobby against public interests, and violate our constitutional rights to make healthcare choices. Through financial power, regulatory influence, and digital censorship, they maintain high drug prices and limit access to affordable medications. Reform is urgently needed to ensure transparency, accountability, and a healthcare system that serves the needs of the people.

How Payment Processors and Shadow Regulation Prevent Americans from Accessing Affordable Generic Pharmaceuticals from India

Brian RogersMay 31, 20240170 views

Americans seeking affordable healthcare solutions often turn to generic pharmaceuticals from countries like India. However, they face significant barriers in using common payment methods such as Visa, MasterCard, PayPal, and Venmo to purchase these medications. This article explores how shadow regulation, particularly by LegitScript, influences payment processors to block transactions related to online pharmacies, and how Big Pharma and government collusion perpetuate these obstacles. The narrative portrays online generic pharmacies as fraudulent, while in reality, this is a form of commercial protectionism benefitting a select few. By recognizing these challenges and advocating for transparency, consumers can better navigate the complex landscape of pharmaceutical access.

Analyzing the Contradiction: U.S. Funding WHO and the Paradox of Indian Pharmaceuticals

Brian RogersMay 31, 20240132 views

The United States is one of the largest contributors to the World Health Organization (WHO), funding initiatives that heavily depend on affordable, generic medications from India. Despite supporting global health programs with Indian generics, the U.S. remains reluctant to embrace these same cost-effective solutions domestically. This paradox highlights the influence of pharmaceutical lobbying and raises ethical questions about healthcare affordability and access. The contrast between supporting international health initiatives and restricting domestic use of Indian generics calls for a reevaluation of U.S. healthcare policies to better align with global health standards and patient needs.

Healthcare Tyranny: The Stranglehold of Big Pharma and Government Overreach

Brian RogersMay 30, 20240179 views

In the U.S., an alarming alliance between big pharma, congressional elites, and government agencies is transforming healthcare into a system of control and oppression. Through extensive lobbying and financial contributions, big pharma has captured the legislative process, ensuring healthcare policies prioritize profit margins over patient well-being. Government agencies like the FDA enforce monopolistic practices, restricting access to affordable medications. This article explores the dire consequences of this collusion and calls for reclaiming healthcare freedom by breaking monopolies and expanding access to affordable medications from trusted international sources.

The Impending Collapse of U.S. Healthcare: A Tale of Neglect and Corporate Greed

Brian RogersMay 29, 20240155 views

The United States is on the brink of a healthcare catastrophe, driven by skyrocketing costs and limited access to essential services. This deepening crisis, perpetuated by political negligence and regulatory capture, threatens the health and well-being of millions. The soaring cost of healthy food has compounded the crisis, fueling rising rates of obesity, diabetes, and heart disease. Additionally, younger generations are burdened with higher taxes to support an inefficient system. Without significant reform, the U.S. risks a diminished role on the world stage and a domestic crisis characterized by economic stagnation and social unrest.

Health or Wealth? The Cost of Big Pharma’s Influence on U.S. Healthcare Policy

Brian RogersMay 29, 20240122 views

Year after year, the pharmaceutical industry ranks among the top spenders in lobbying efforts in Washington, D.C., pouring hundreds of millions into influencing drug approval processes and pricing. This financial influence secures patents and market exclusivity for new drugs, creating monopolies that keep prices high and limit affordable alternatives. Platforms like Ashvin Medicara offer transparency and education about cost-effective pharmaceuticals. It’s crucial for the public to demand open dialogues and reforms to prioritize accessible and affordable healthcare for all.